MatchMedi
English

선택지 정리됨

Pompe disease: 국가별 선택지

이 페이지는 한국어 임상 치료 설명을 새로 쓰지 않습니다. 권위 출처, 진료 전 정리 질문, 임상시험 검색어, 구축 상태를 보여주는 안전한 시작점입니다.

선택지 정리됨희귀·유전 질환최종 확인 2026.06

현재 제공

국가별 선택지를 정리합니다

국가별로 출처가 연결된 선택지와 함께, 진단명·단계·검사 결과·진료과·임상시험 검색어를 정리합니다.

아직 하지 않음

치료 선택을 지시하지 않습니다

이 페이지는 치료 순위, 권장, 적합성 판단을 하지 않습니다.

출처

공신력 있는 출처 기반

모든 선택지는 규제·평가·지침 등 공신력 있는 출처에 연결되며, 새 출처가 검증되면 계속 확장됩니다.

진료 전 정리할 정보

  • 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
  • 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
  • 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
  • 이 항목은 원문 출처와 함께 의료진에게 확인하세요.

임상시험 검색어

Pompe disease clinical trial

국가별 선택지

국가별 치료 선택지

공식 규제·평가 기관 출처를 바탕으로 한 국가별 승인·접근 상태입니다. 무엇이 어디에 존재하는지를 보여줄 뿐, 추천이 아닙니다.

United States

  • Alglucosidase alfa (Lumizyme); avalglucosidase alfa-ngpt (Nexviazyme); cipaglucosidase alfa-atga (Pombiliti) plus miglustat (Opfolda)[1]FDA-approvedGAA deficiency; GAA gene mutations in registry/trial criteria; Lumizyme broad Pompe disease ERT; Nexviazyme late-onset Pompe disease age 1+; Pombiliti/Opfolda adult late-onset Pompe disease after insufficient improvement on current ERT. · Lumizyme and Nexviazyme labels include hypersensitivity/infusion reaction and cardiorespiratory monitoring precautions. Pombiliti must be used with Opfolda, and Opfolda must be timed with Pombiliti; pregnancy and renal considerations are noted in labeling. Confidence/conflicts: High for U.S. FDA-label claims. No payer access or comparative benefit is inferred.
  • Alglucosidase alfa (Lumizyme); avalglucosidase alfa-ngpt (Nexviazyme); cipaglucosidase alfa-atga (Pombiliti) plus miglustat (Opfolda)[1]FDA-approvedGAA deficiency; GAA gene mutations in registry/trial criteria; Lumizyme broad Pompe disease ERT; Nexviazyme late-onset Pompe disease age 1+; Pombiliti/Opfolda adult late-onset Pompe disease after insufficient improvement on current ERT. · Lumizyme and Nexviazyme labels include hypersensitivity/infusion reaction and cardiorespiratory monitoring precautions. Pombiliti must be used with Opfolda, and Opfolda must be timed with Pombiliti; pregnancy and renal considerations are noted in labeling. Confidence/conflicts: High for U.S. FDA-label claims. No payer access or comparative benefit is inferred.
  • Alglucosidase alfa (Lumizyme); avalglucosidase alfa-ngpt (Nexviazyme); cipaglucosidase alfa-atga (Pombiliti) plus miglustat (Opfolda)[1]FDA-approvedGAA deficiency; GAA gene mutations in registry/trial criteria; Lumizyme broad Pompe disease ERT; Nexviazyme late-onset Pompe disease age 1+; Pombiliti/Opfolda adult late-onset Pompe disease after insufficient improvement on current ERT. · Lumizyme and Nexviazyme labels include hypersensitivity/infusion reaction and cardiorespiratory monitoring precautions. Pombiliti must be used with Opfolda, and Opfolda must be timed with Pombiliti; pregnancy and renal considerations are noted in labeling. Confidence/conflicts: High for U.S. FDA-label claims. No payer access or comparative benefit is inferred.

European Union

  • Avalglucosidase alfa (Nexviadyme); cipaglucosidase alfa (Pombiliti) plus miglustat (Opfolda)[2]EMA authorisedAcid alpha-glucosidase (GAA) deficiency; Long-term ERT for Pompe disease; adult late-onset Pompe disease Pombiliti/Opfolda pathway. · EMA authorization is EU-wide but member-state reimbursement/access differs. NICE is England-specific and reuse-restricted/link-only. France/Germany reimbursement was not verified in this cell. Confidence/conflicts: High for EMA/NICE statements; national reimbursement gaps remain.
  • Avalglucosidase alfa (Nexviadyme); cipaglucosidase alfa (Pombiliti) plus miglustat (Opfolda)[2]EMA authorisedAcid alpha-glucosidase (GAA) deficiency; Long-term ERT for Pompe disease; adult late-onset Pompe disease Pombiliti/Opfolda pathway. · EMA authorization is EU-wide but member-state reimbursement/access differs. NICE is England-specific and reuse-restricted/link-only. France/Germany reimbursement was not verified in this cell. Confidence/conflicts: High for EMA/NICE statements; national reimbursement gaps remain.

Japan

  • avalglucosidase alfa, genetically recombinant (Nexviazyme)[3]PMDA-approved (Japan)acid alpha-glucosidase (GAA) deficiency context; treatment of Pompe disease; the fetched PMDA list does not limit the indication to infantile- or late-onset disease. · The PMDA deliberation report explains Pompe disease is an autosomal recessive lysosomal disorder due to GAA deficiency and notes prior Japanese alglucosidase approval. This entry does not establish reimbursement, switching criteria from Myozyme, CRIM/immune-tolerance practice, ventilatory/cardiology supportive care, or full current package insert details. Confidence/conflicts: High for Japanese avalglucosidase/Nexviazyme approval and Pompe indication; no conflict identified. Full current label and reimbursement remain gaps.
  • cipaglucosidase alfa (Pombiliti) plus miglustat (Opfolda)[4]PMDA-approved (Japan)acid alpha-glucosidase (GAA) deficiency context; late-onset phenotype; combination therapy for late-onset Pompe disease. · This entry captures PMDA approval/listing evidence, not full package-insert details. It does not establish reimbursement, whether prior ERT exposure is required or excluded, respiratory/motor monitoring expectations, pregnancy considerations, or specialist-center availability. Pombiliti and Opfolda are documented as combination therapy and should not be represented as standalone options from these sources. Confidence/conflicts: High for Japanese Pombiliti/Opfolda approval and late-onset Pompe indication; no conflict identified. Full labels and reimbursement remain gaps.

Australia

  • alglucosidase alfa (Myozyme); avalglucosidase alfa (Nexviazyme)[5]Approvedacid alpha-glucosidase (GAA) deficiency / Pompe disease; Australian LSDP-subsidised enzyme replacement therapy for eligible infantile-onset or late-onset Pompe disease. · LSDP access requires initial and ongoing eligibility criteria and annual reapplication. Home administration for avalglucosidase alfa may be considered only after safety and tolerability are established in the clinical setting. Confidence/conflicts: High for Australian LSDP Myozyme/Nexviazyme access; no conflict identified. Availability/reimbursement outside the approving regulator not established.
  • alglucosidase alfa (Myozyme); avalglucosidase alfa (Nexviazyme)[5]Approvedacid alpha-glucosidase (GAA) deficiency / Pompe disease; Australian LSDP-subsidised enzyme replacement therapy for eligible infantile-onset or late-onset Pompe disease. · LSDP access requires initial and ongoing eligibility criteria and annual reapplication. Home administration for avalglucosidase alfa may be considered only after safety and tolerability are established in the clinical setting. Confidence/conflicts: High for Australian LSDP Myozyme/Nexviazyme access; no conflict identified. Availability/reimbursement outside the approving regulator not established.
  • avalglucosidase alfa (Nexviazyme)[6]TGA-registered (Australia)acid alpha-glucosidase deficiency; long-term enzyme replacement therapy for Pompe disease age one year and older; Australian LSDP access for eligible patients. · The TGA decision summary verifies approval but not individual access. LSDP guideline limits and reapplication criteria apply. Confidence/conflicts: High for Australian Nexviazyme approval and LSDP context; no conflict identified. Availability/reimbursement outside the approving regulator not established.
  • avalglucosidase alfa (Nexviazyme)[6]TGA-registered (Australia)acid alpha-glucosidase deficiency; long-term enzyme replacement therapy for Pompe disease age one year and older; Australian LSDP access for eligible patients. · The TGA decision summary verifies approval but not individual access. LSDP guideline limits and reapplication criteria apply. Confidence/conflicts: High for Australian Nexviazyme approval and LSDP context; no conflict identified. Availability/reimbursement outside the approving regulator not established.
  • cipaglucosidase alfa (Pombiliti) plus miglustat 65 mg (Opfolda)[7]TGA-registered (Australia)acid alpha-glucosidase (GAA) deficiency; adult late-onset Pompe disease combination ERT plus enzyme stabiliser in Australia. · The AusPAR verifies TGA registration/indication but not PBS or LSDP funding. Pregnancy category D and contraception/pregnancy cautions are described in the AusPAR. Confidence/conflicts: High for Australian regulatory indication; funding status remains source-pending. Availability/reimbursement outside the approving regulator not established.
  • cipaglucosidase alfa (Pombiliti) plus miglustat 65 mg (Opfolda)[7]TGA-registered (Australia)acid alpha-glucosidase (GAA) deficiency; adult late-onset Pompe disease combination ERT plus enzyme stabiliser in Australia. · The AusPAR verifies TGA registration/indication but not PBS or LSDP funding. Pregnancy category D and contraception/pregnancy cautions are described in the AusPAR. Confidence/conflicts: High for Australian regulatory indication; funding status remains source-pending. Availability/reimbursement outside the approving regulator not established.

Thailand

  • alglucosidase alfa (Myozyme)[8]Approvedconfirmed acid alpha-glucosidase (GAA) deficiency; long-term enzyme replacement therapy for confirmed Pompe disease in adult and pediatric patients. · The label states treatment should be supervised by a physician experienced in Pompe disease or other inherited metabolic or neuromuscular diseases. It includes severe hypersensitivity/anaphylaxis and infusion-associated-reaction precautions, routine response evaluation across clinical manifestations, and does not establish Thai reimbursement or stock availability. Confidence/conflicts: High for Thai Myozyme label and authorization details; no conflict identified, but reimbursement and care-pathway details remain unresolved.
  • avalglucosidase alfa (Nexviazyme)[9]Approvedconfirmed acid alpha-glucosidase (GAA) deficiency; infantile-onset versus late-onset context relevant; long-term enzyme replacement therapy for Pompe disease; source includes dose-modification context for infantile-onset Pompe disease patients with insufficient cardiac, respiratory, and/or motor response while receiving the standard dose. · The label states treatment should be supervised by a physician experienced in Pompe disease or other inherited metabolic or neuromuscular diseases. It notes no established data for patients 6 months of age and younger, hypersensitivity/anaphylaxis and fluid-overload considerations, and does not establish Thai reimbursement or center availability. Confidence/conflicts: High for Thai Nexviazyme label and authorization details; no conflict identified, but reimbursement and switching/access pathways remain unresolved.

Canada

  • avalglucosidase alfa (Nexviazyme)[10]Approvedacid alpha-glucosidase deficiency; long-term ERT for late-onset Pompe disease in Canada. · The product monograph excludes infantile-onset Pompe disease from the indication. CADTH review informs payer decisions but provincial implementation remains separate. Confidence/conflicts: High for Canadian label; medium-high for payer context because implementation varies by public plan.
  • avalglucosidase alfa (Nexviazyme)[10]Approvedacid alpha-glucosidase deficiency; long-term ERT for late-onset Pompe disease in Canada. · The product monograph excludes infantile-onset Pompe disease from the indication. CADTH review informs payer decisions but provincial implementation remains separate. Confidence/conflicts: High for Canadian label; medium-high for payer context because implementation varies by public plan.
  • cipaglucosidase alfa (Pombiliti) plus miglustat 65 mg (Opfolda)[11]Health Canada approvedacid alpha-glucosidase (GAA) deficiency; adult late-onset Pompe disease weighing at least 40 kg; Pombiliti plus Opfolda combination therapy. · The product monograph lists serious warnings for hypersensitivity/anaphylaxis and infusion-associated reactions, contraindicates use with Opfolda in pregnancy, and states both medicinal products should be continued or discontinued together. Reimbursement implementation was not established from these sources. Confidence/conflicts: High for Canadian approval and label constraints; reimbursement status remains source-pending.
  • cipaglucosidase alfa (Pombiliti) plus miglustat 65 mg (Opfolda)[11]Health Canada approvedacid alpha-glucosidase (GAA) deficiency; adult late-onset Pompe disease weighing at least 40 kg; Pombiliti plus Opfolda combination therapy. · The product monograph lists serious warnings for hypersensitivity/anaphylaxis and infusion-associated reactions, contraindicates use with Opfolda in pregnancy, and states both medicinal products should be continued or discontinued together. Reimbursement implementation was not established from these sources. Confidence/conflicts: High for Canadian approval and label constraints; reimbursement status remains source-pending.

출처

  1. U.S. Food and Drug Administration — official drug label · official drug label
  2. European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
  3. Pharmaceuticals and Medical Devices Agency (PMDA) — regulator deliberation report PDF · regulator deliberation report PDF
  4. Pharmaceuticals and Medical Devices Agency (PMDA) — approved drugs list PDF · approved drugs list PDF
  5. Australian Government Department of Health, Disability and Ageing — LSDP resource collection · LSDP resource collection
  6. Therapeutic Goods Administration (TGA) — Australian prescription medicine decision summary · Australian prescription medicine decision summary
  7. Therapeutic Goods Administration (TGA) — Australian Public Assessment Report · Australian Public Assessment Report
  8. Thai National Drug Information / Thai FDA-MOPH — SmPC PDF / regulator drug-information repository · SmPC PDF / regulator drug-information repository
  9. Thai National Drug Information / Thai FDA-MOPH — SmPC PDF / regulator drug-information repository · SmPC PDF / regulator drug-information repository
  10. Sanofi-aventis Canada / Health Canada product monograph — official product monograph · official product monograph
  11. Health Canada Drug and Health Products Portal — Summary Basis of Decision · Summary Basis of Decision

위 내용은 공식 규제·접근 상태일 뿐, 의학적 조언이나 추천이 아니고, 적격성을 판단하지도 않습니다. 어떤 선택지가 적합한지는 환자의 상황과 종양내과 팀에 달려 있습니다. 규제 상태는 바뀔 수 있으니 표시된 출처에서 확인하세요. 임상 세부 내용은 영문이 정본입니다. 최종 확인 2026-06-12.